Unicycive Therapeutics (NASDAQ:UNCY – Get Rating) is one of 939 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Unicycive Therapeutics to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Insider and Institutional Ownership
19.3% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 45.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Unicycive Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Unicycive Therapeutics Competitors||6397||21064||43294||870||2.54|
Unicycive Therapeutics currently has a consensus target price of $8.25, indicating a potential upside of 944.30%. As a group, “Pharmaceutical preparations” companies have a potential upside of 131.09%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than its competitors.
This table compares Unicycive Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Unicycive Therapeutics Competitors||-3,162.45%||-1,570.56%||-9.70%|
Earnings and Valuation
This table compares Unicycive Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Unicycive Therapeutics||N/A||-$10.02 million||-0.87|
|Unicycive Therapeutics Competitors||$1.86 billion||$248.94 million||-1.48|
Unicycive Therapeutics’ competitors have higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Unicycive Therapeutics Company Profile (Get Rating)
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.